Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor

British Journal of Cancer

Volumn 87, Issue 1, 2002, Pages 119-126

  Shi, W ^a   Siemann, D W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Angiogenesis; Antisense oligodeoxynucleotides; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL GROWTH FACTORS; FEMALE; KIDNEY NEOPLASMS; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIONUCLEOTIDES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036648424     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600416     Document Type: Article

References (60)

1. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121
2. Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer
3. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene
4. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies
5. Anticancer strategies involving the vasculature: Vascular targeting and the inhibition of angiogenesis
6. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
7. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
8. The tumour microcirculation as a target in cancer therapy: A clearer perspective
9. VEGF and vascular fusion: Implications for normal and pathological vessels
10. Antisense RNA
11. Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation
12. Antisense oligodeoxynucleotide technology: Potential use for the treatment of malignant brain tumors
13. Molecular and biological properties of vascular endothelial growth factor
14. Tumor angiogenesis: Therapeutic implications
15. Angiogenesis inhibitors generated by tumors
16. Control of angiogenesis by heparin and other sulfated polysaccharides
17. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
18. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule
19. Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin
20. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
21. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer
22. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
23. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
24. Serum vascular endothelial growth factor is a candidate biomarker of renal cell carcinoma in hemodialysis patients
25. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma
26. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor
27. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
28. Vascular endothelial growth factor is a secreted angiogenic mitogen
29. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
30. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
31. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
32. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
33. Epidemiologic aspects of renal cell cancer
34. Antisense approaches to cancer gene therapy
35. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
36. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma
37. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
38. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
39. Angiostatin: A circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth
40. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
41. Expression of vascular endothelial growth factor in renal cell carcinomas
42. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors
43. Basic principles of using antisense oligonucleotides in vivo
44. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
45. Mechanisms of angiogenesis
46. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
47. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma
48. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma
49. Lymphocyte-induced angiogenesis in tumor-bearing mice
50. Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes
51. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7- encoded domain of VEGF165
52. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
53. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
54. Synthesis of a single-tailed cationic lipid and investigation of its transfection
55. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
56. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
57. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
58. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
59. United Kindom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia
60. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma